The intellectual property ImmuneCyte has purchased includes four monoclonal antibody drug candidates against SARS-CoV-2, which were obtained from B cell samples from patients who recovered from the disease. The drug candidates were initially developed by researchers at East China Normal University in Shanghai.

ThermoGenesis is also developing a treatment called convalescent plasma therapy that gives patients a plasma infusion from people who have recovered from COVID-19 using its SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection kit, it said.

SARS-CoV-2 vaccine utilizing microneedle arrays appears in the literature
Within four weeks of the SARS-CoV-2 spike sequence becoming available, researchers from the University of Pittsburgh School of Medicine developed immunogens...

Applied DNA, Takis expand COVID-19 vaccine development
Applied DNA and Takis Biotech have added a fifth candidate to their COVID-19 vaccine development program, increasing the chances of a successor emerging.